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Abstract: Objective: Female infections affecting the genital tract include sexually transmitted diseases,
endogenous infections such as vulvovaginal candidiasis, bacterial vaginosis (BV) or aerobic vaginitis
(AV) and healthcare-associated infections. The aim of the study was to analyze the etiological factors
of the vaginal dysbacteriosis, and the antimicrobial susceptibility of the dominant bacterial and
fungal infections in different age groups of outpatient women from the Silesian Region. Materials
and methods: A retrospective laboratory-based multi-center study encompassed 4994 women of
different ages in Silesian Voivodeship, in the south of Poland; patients who had vaginal swabs
collected as per physicians’ orders during the period from 1 January 2017 until 30 June 2018 were
included in the study. The inclusion criteria were: non-hospitalized female, aged ≤80, with suspected
vulvovaginal candidiasis or bacterial vaginosis and clinical sings of infections. Results: Gram-positive
cocci were the ones most often isolated: Enterococcus faecalis (29.2%) and Streptoccoccus agalactiae
(13.1%), followed by bacilli from the Enterobacteriaceae group, including Escherichia coli (26.3%). The
presence of Streptococcus agalactiae was confirmed in 13.1%, slightly more often in the 45–80 age group,
and Gardnerella vaginalis in 6.4%, most often in women aged 15–24. The prevalence of yeast-like
infections was 24.3%, Candida albicans accounted for 78.3%, whereas among C. non-albicans spp.—C.
glabrata dominated (14.9%) followed by C. parapsilosis (3.8%). The highest resistance was observed
only in Streptococcus agalactiae as the MLSB mechanism (Macrolide-lincosamide-streptogramin B)
was identified in 38.6% of strains. The prevalence of vulvovaginal candidiasis was 24.3%, the highest
in women aged 15–44. Conclusions: Drug resistance in studied vulvovaginitis was associated only
with Streptococcus agalactiae. A high proportion of yeast-like aetiology was found, probably associated
with recurrent infections. In the analyzed cases only the Amsel criteria and culture methods were
used for diagnosis without preparations and microbiological Nugent criteria.
Keywords: vaginal infections; lower genital tract; Escherichia coli; Candida spp.
1. Introduction
The bacterial flora in the vagina of a healthy woman of reproductive age is dominated
by lactobacilli. Besides of Lactobacillus species, the following bacterial genera may also be
isolated from the female genital tract: Streptococcus, Staphylococcus, Enterococcus, Escherichia
and Klebsiella, as well as Candida yeasts. Female infections affecting the genital tract include
sexually transmitted diseases, endogenous infections such as vulvovaginal candidiasis,
bacterial vaginosis (BV) or aerobic vaginitis (AV) and healthcare-associated infections [1,2].
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In a healthy woman, vaginal microorganisms are mutually antagonistic and inter-
dependent, maintaining a dynamic balance regulated by the endocrine system and the
local immune system and influenced by the internal environment of the vagina [3]. The
composition of microbiota may vary considerably depending on the age of the woman,
hormone management, sexual activity, as well as exposure to hygienic substances used in
vaginal irrigation.
In developed countries, overgrowth of endogenous bacteria normally found in the
vagina is usually the most common cause of vaginal discharge in women of reproductive
age. In this case of bacterial dysbiosis a shift in vaginal microbiota from lactobacilli domi-
nation to an increased growth of mixed anaerobes in BV (Gardnerella vaginalis, Mobiluncus
sp., Bacteroides spp.) and aerobes in AV (group B streptococci, enterococci and Escherichia
coli) are detected.
If an uncomplicated urogenital tract infection is diagnosed, empirical treatment is
used. However, untreated or misdiagnosed vaginal infections can lead to pelvic inflam-
matory diseases and tubal infertility and ectopic pregnancy consequently, treatment of
BV- and AV-associated bacteria may increase the vaginal reservoir of antibiotic-resistant
strains. Polish data on the bacterial and fungal etiology of infections of the lower part of the
reproductive system, let alone the antibiotic susceptibility, have not been collected. Mean-
while, implementing an antibiotic stewardship program (ASP) should be based on local
data/local epidemiology: antibiograms and lab data, showing susceptibility of specific
organisms to specific drugs in specific disease [4]. ASPs, by which we mean coordinated
interventions designed to improve and measure the appropriate use of antibiotics by pro-
moting the selection of the optimal pharmacotherapy, are also recommended in outpatient
settings. However, the authors’ observations are quite different: antibiotic consumption in
Poland is much higher than the European average [5]. Female patients are no exception,
e.g., almost a quarter of Polish pregnant women and more than 7% of women in labor
purchased antibiotics prescribed by the obstetrician [6,7]. Therefore, knowledge of the local
epidemiology of infections should help physicians to conduct rational empirical antibiotic
therapy.
The aim of the study was to analyze BV and AV associated bacteria and yeast strains
isolated from vagina of women with and without symptoms of vaginal inflammation
(pain, pruritus and dyspareunia) and vaginal discharge; and the results of antimicrobial
susceptibility of the dominant bacterial and fungal etiological factors in outpatients of
different age groups from the Silesian Voivodeship.
2. Materials and Methods
Retrospective laboratory-based multicenter study encompassed 4994 vaginal smears
from women of different age in Silesian Voivodeship, the south of Poland. Patients who had
vaginal swabs collected as per physicians’ orders during the period from 1 January 2017
to 30 June 2018 were included in the study. The inclusion criteria were non-hospitalized
girls or women with and without symptoms of vaginal inflammation (pain, pruritus,
dyspareunia) and vaginal discharge. Women excluded from the study were those over
80 years of age (n = 29), hospitalized, or suffering from typical sexually transmitted
diseases, e.g., gonorrhoea, syphilis, chlamydia, trichomoniasis, human papillomavirus,
genital herpes, HIV.
Vaginal discharge and swabs were collected using sterile cotton swabs, in lithotomy
position, under aseptic conditions. These swabs were then transported to the diagnostic
microbiology laboratory. Bacteria associated with AV and BV and fungi were identified
using MALDI-TOF Biotyper (Biotyper Bruker Daltonics, Leiderdorp, The Netherlands)
system according to the manufacturer’s instructions. The analysis of microbial etiology
was carried out with stratification according to the age of patients. In as many as 18.8% of
patients, rare species of bacteria were isolated, which were identified in not more than in
2% of all clinical samples—these were not subject to any further detailed analysis and are
described in Table 1 as “other bacteria”.
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Table 1. Distributions of the microorganisms in infections of the female reproductive tract in women from the south of Poland.
Microorganisms
Age of Patients (Years) n (%)
Range
≤14 15–24 25–34 35–44 45–54 55–64 65–80 BD Total
Gram-positive
Staphylococcus aureus 0 (0.0) 23 (4.3) 62 (2.8) 25 (1.9) 7 (1.9) 9 (4.0) 6 (2.8) 1 (3.8) 135 (2.7) 8
Enterococcus faecalis 26 (31.7) 117 (21.8) 651 (28.9) 360 (27.8) 121 (32.9) 80 (35.7) 96 (44.0) 7 (26.9) 1458 (29.2) 1
Enterococcus faecium 0 (0.0) 0 (0.0) 2 (0.1) 1 (0.1) 1 (0.3) 0 (0.0) 1 (0.5) 0 (0.0) 5 (0.1) 10
Enterococcus spp. 2 (2.4) 0 (0.0) 1 (0.0) 0 (0.0) 0 (0.0) 1 (0.4) 3 (1.4) 0 (0.0) 7 (0.1) 10
Streptococcus agalactiae, GBS 2 (2.4) 76 (14.2) 274 (12.2) 160 (12.3) 65 (17.7) 41 (18.3) 37 (17.0) 2 (7.7) 657 (13.1) 4
Gardnerella vaginalis 0 (0.0) 55 (10.3) 158 (7.0) 72 (5.6) 22 (6.0) 11 (4.9) 2 (0.9) 2 (7.7) 322 (6.4) 5
Gram-negative
Escherichia coli 39 (47.6) 113 (21.1) 553 (24.5) 298 (23.0) 115 (31.3) 80 (35.7) 106 (48.6) 6 (23.1) 1309 (26.2) 2
Klebsiella pneumoniae 4 (4.9) 21 (3.9) 94 (4.2) 49 (3.8) 15 (4.1) 12 (5.4) 14 (6.4) 0 (0.0) 209 (4.2) 7
Klebsiella oxytoca 0 (0.0) 0 (0.0) 11 (0.5) 2 (0.2) 3 (0.8) 5 (2.2) 3 (1.4) 1 (3.8) 25 (0.5) 8
Klebsiella mobilis 1 (1.2) 0 (0.0) 8 (0.4) 4 (0.3) 0 (0.0) 1 (0.4) 2 (0.9) 0 (0.0) 16 (0.3) 9
Klebsiella spp. 0 (0.0) 0 (0.0) 1 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.01) 11
other bacteria * 31 (37.8) 95 (17.7) 422 (18.7) 220 (17.0) 61 (16.6) 40 (17.9) 61 (28.0) 3 (11.5) 933 (18.7)
Candida spp. 7 (8.5) 173 (32.3) 564 (25.0) 339 (26.2) 80 (21.7) 28 (12.5) 22 (10.1) 6 (23.1) 1219 (24.4) 3
Negative result 31 (37.8) 160 (29.9) 665 (29.5) 410 (31.6) 133 (36.1) 82 (36.6) 65 (29.8) 9 (34.6) 1555 (31.1)
Total no. of patients 82 (100) 536 (100) 2253 (100) 1296 (100) 368 (100) 224 (100) 218 (100) 26 (100) 4994 (100%)
* The species or families of strains whose isolation was over 100.
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All bacteria strains were tested using disk diffusion antimicrobial susceptibility
methods on Mueller-Hinton agar plates according to current guidelines of the Euro-
pean Committee on Antimicrobial Susceptibility Testing (Clinical breakpoints tables v.6.0;
http://www.eucast.org v.6.0), but cefoperazone/sulbactam according to the manufac-
turer’s instructions and the results were considered resistant (R) and susceptible (S), with
intermediately resistant strains grouped together as drug-resistant. The initial antibiogram
included antibiotics indicated in Table 1, for strains initially identified as drug-resistant,
only ESBL-E. coli (extended-spectrum beta-lactamases producing E. coli) antibiogram was
supplemented and they were: cefepim, ceftazidime and cefoperazone/sulbactam. All disks
were obtained from Oxoid (Basingstoke, UK). The susceptibility of Candida spp. has not
been tested [8].
The analysis of antibiotic susceptibility focused only on the most numerous microor-
ganisms isolated (Enterococcus faecalis, Escherichia coli and Streptoccoccus agalactiae) and the
age groups for which more than 5% of the total tests were performed, i.e., 15–54 years
of age.
The database was compiled by the Chair of Microbiology at the Jagiellonian University
Medical College (Cracow, Poland), and the collaborating laboratory from the Silesia region
(Korlab Medical Laboratories, Ruda Śląska, Poland).
3. Results
The group of studied women was dominated by patients aged 25–44, which consti-
tuted 70.7% of all examined. The test was performed least often in girls up to 14 years of
age (1.6%) and in this age group a negative test was most often obtained (37.8%, Table 1).
AV-associated bacteria such as Gram-positive cocci were the ones most often isolated:
Enterococcus faecalis (29.2%) and Streptoccoccus agalactiae (13.1%), followed by bacilli from
the Enterobacteriaceae group, including Escherichia coli (26.3%). The presence of Streptococcus
agalactiae was confirmed in 13.1%, slightly more often in the 45–80 age group. BV associated
Gardnerella vaginalis strains were detected in 6.4%, most often in women aged 15–24.
Yeast-like infections occurred in 24.3% of patients, more commonly in women aged
15–44, while in patients aged 55 and older, they accounted for only 12.5–10.1%, respectively
(Table 1). Candida albicans accounted for 78.3%, whereas among C. non-albicans spp.—C.
glabrata dominated (14.9%) followed by C. parapsilosis (3.8%).
In the studied age ranges, Enterococcus faecalis retained susceptibility to penicillins and
aminoglycosides, although the high-level aminoglycoside resistance mechanism, HLAR,
featured in 26.0% of strains.
Often isolated Escherichia coli rods showed high or medium susceptibility to amino-
glycosides, less susceptibility to fluoroquinolones and trimethoprim/sulfamethoxazole.
Of the antibiotics frequently used in genital tract infections, the lowest susceptibility was
found to be with ampicillin. The ESBL mechanism was found in 3.6% of strains—these
strains also showed very low susceptibility to third and fourth generation cephalosporins
(Table 2).
Streptococcus agalactiae remained susceptible to penicillin and trimethoprim/
sulfamethoxazole. Strains from patients aged 45–54 were found to be resistant to clin-
damycin and erythromycin (Table 2), and in general, the MLSB (Macrolide-lincosamide-
streptogramin B) mechanism was identified in 38.6% of strains, mainly cMLSB (33.7%).
(Table 2)
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Table 2. Antimicrobial susceptibility of selected microorganisms isolated from infections according to patients’ age.
Antimicrobial/Strain
Patient Age (Years)
15–24 25–34 35–44 45–54 Total
Enterococcus faecalis susceptibility (%)
Ampicillin (5 µg) 100.0 100.0 100.0 100.0 100
Gentamicin High Level (synergy) (30 µg) 79.2 81.6 78.4 78.4 79.7
Streptococcus agalactiae, GBS susceptibility (%)
Benzylpenicillin (1 unit) 100.0 100.0 100.0 100.0 100.0
Clindamycin (2 µg) 71.1 72.4 67.3 51.5 69.2
Erythromycin (15 µg) 68.4 69.5 64.8 53.0 66.9
Trimethoprim/ Sulfamethoxazole (1.25/23.75 µg) 98.7 98.9 98.1 97.0 98.6
Escherichia coli susceptibility (%)
Aminoglycosides
Gentamicin (10 µg) 95.6 96.2 95.4 93.9 95.0
Tobramycin (10 µg) 100.0 61.9 90.9 66.7 68.2
Amikacin (30 µg) 100.0 85.7 100.0 88.9 87.9
Non-extended spectrum cephalosporins; 1st and 2nd generation cephalosporins
Cefuroxime (30 µg) 97.3 96.0 97.0 95.7 96.0
Extended-spectrum cephalosporins; 3rd and 4th generation cephalosporins
Cefotaxime (5 µg) 97.3 97.1 97.3 95.7 96.8
Ceftazidime * (n = 66) (10 µg) 0.0 50.0 54.5 62.5 54.0
Cefepime * (n = 66) (30 µg) 50.0 45.5 45.5 44.4 47.0
Cefoperazone/Sulbactam * (n = 66) (75/30 µg) 66.7 100.0 100.0 100.0 98.4
Fluoroquinolones
Ciprofloxacin (5 µg) 84.6 85.2 85.2 83.6 82.5
Folate pathway inhibitors
Trimethoprim/Sulfamethoxazole (1.25/23.75 µg) 81.4 79.4 80.1 70.1 76.6
Penicillins
Ampicillin (10 µg) 53.5 47.9 51.9 48.8 49.0
Piperacillin/Tazobactam (30/6 µg) 100.0 90.5 100.0 100.0 90.9
Penicillins + b-lactamase inhibitors
Ampicillin/Sulbactam (10/10 µg) 86.0 80.3 85.0 78.5 81.1
* Studied only in drug resistant strains, ESBL-E. coli.
4. Discussion
It is puzzling that despite the fact that the vaginal flora and vaginal infections have
been the topics of interest to physicians and scientists alike, for many years now, there
is still much to be learned and newer scientific reports are continuing to improve our
understanding of the vaginal flora and microbiology of infections. This is also the case
in Poland, where such microbiology and antimicrobial resistance of infections are not
described in detail, except for the phenomenon of Streptococcus agalactiae colonization
among pregnant women [9,10].
Streptococcus agalactiae (GBS) is an important infectious agent in pregnant women and
non-pregnant adults; in the studied population it was the fourth most-isolated microbe
with a prevalence 13%. GBS can stimulate human cell lines in vitro (HeLa, THP-I and U
937) to release proinflammatory cytokines (IL-6, IL-8, TNF-α) [11]. However, above all, GBS
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emerged as the leading cause of neonatal sepsis, therefore, it is recommended to use either
antenatal screening for GBS colonization and intrapartum antimicrobial prophylaxis (IAP)
in colonized women or administer IAP to women with certain obstetric risk factors during
labor. Penicillin is the first choice for intrapartum antibiotic prophylaxis, with ampicillin
as an acceptable alternative for penicillin-allergic women at high risk for anaphylaxis:
clindamycin [12]. Unfortunately, the presented data indicate high resistance to clindamycin
and erythromycin, which is also confirmed by other Polish authors [13], but our data
indicated also high resistance to ampicillin. Thus, a large proportion of GBS showing
high drug resistance is a significant problem, of great importance to the reproductive
health of Polish women, as evidenced by the polish Public Opinion Research Centre survey,
according to which 41% of women aged 18–45 are planning offspring [14].
Numerous authors have indicated that the abnormal genital tract colonization, not
only GBS, may lead to an in-utero inflammation/infectious process, and in pregnant women
bacterial vaginosis may cause complications such as premature rupture of membranes
and preterm delivery, respiratory distress syndrome or necrotizing enterocolitis (NEC) in
preterm infants—especially E. faecalis (the most common microorganisms in our study)
increased the risk for NEC [15]. Therefore, another important clinical problem in women
of childbearing age is also AV, when owing to disappearance of Lactobacillus strains, mixed
aerobic bacterial flora, mostly GBS, Enterococcus spp. and E. coli multiply. The development
of purulent vaginal discharge in case of AV may be the cause of numerous complications,
especially in pregnant women, which may predispose to infections from the vagina to
higher sections of the reproductive system and premature rupture of membranes (PROM),
miscarriages and premature delivery [16–18].
Microflora in desquamative inflammatory vaginitis usually consists of E. coli, Staphy-
lococcus aureus, GBS and Enterococcus faecalis [19,20]. Unfortunately, our research found
a high prevalence of Escherichia coli, which can colonize the vagina but also lead to the
replacement of natural microflora, by eliminating lactobacilli. In cases of AV, as compared
to GBS and Enterococcus spp., it is less often isolated, but during pregnancy it may be
the cause of habitual miscarriages, chorioamnionitis and premature birth [21]. It can also
increase the risk of early severe infections in a newborn [22,23]. In Poland, in very low birth
weight neonates, E. coli constituted 12% of the pathogens isolated from neonatal sepsis and
fatality case rate was 33% [24].
Treating bacterial vaginosis with different etiology during pregnancy can reduce poor
outcomes, such as preterm birth, so WHO recommends not only treating symptomatic
infections but also screening for vaginosis in pregnant women and women with a history
of spontaneous abortion or preterm delivery [1,25], because it may be related to infertility.
On the other hand, according to PREMEVA results, a double-blind randomized controlled
trial done in 40 French facilities—screening and treatment of bacterial vaginosis in women
without high-risk pregnancies shows no evidence of risk reduction of late miscarriage or
spontaneous preterm birth [26].
Vaginal microbiota is essentially different during the individual periods in a woman’s
life, and its species composition depends mainly on hormone management, sexual activ-
ity and the efficient functioning of local immune mechanisms, associated with mucosa-
associated lymphoid tissue (MALT), as well as systemic mechanisms. In the analyzed group
of sexually active outpatient patients of childbearing age, up to 45 years, Candida albicans
was the most frequently isolated fungus, which caused lower genital tract infections in
about a third of women aged 15–24. Moreover, Gardnerella vaginalis strains were isolated
from women, whose participation in the pathogenesis, both qualitative and quantitative
disorders of the vaginal microbiota, with the disappearance of Lactobacillus strains (result-
ing in the formation of BV)—and specific discharge decreases significantly after the age
of 54.
Vaginal infections caused by Candida spp. and BV are a therapeutic problem in the
group of outpatients, due to their frequent recurrent character. These infections may
impair the functioning of immune mechanisms, favoring the promotion and progression
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of HPV-dependent dysplastic changes in the cervical epithelium. In the studies of Ekiel
et al. in women with an average age of 38 years with the diagnosis of cytological changes
of ASCUS type (atypical squamous cells of undetermined significance), showed Candida
albicans strains and no lactobacilli were isolated. In comparison to the control group of
30-year-old women without any dysplastic lesions of the cervical epithelium, GBS strains
and gram-negative bacilli were also more often isolated from the vagina [27].
Unfortunately, vulvovaginal candidiasis may also be related to infertility problems [28]
and we observed a very high level of yeast infections, about a quarter of all had such aetiol-
ogy, certain medical conditions, e.g., pregnant women and women using oral contraceptives
(changes in vaginal acidity, pH) or diabetes may increase the risk of yeast infections. Less
commonly, recurrent yeast infections may be a sign of a more serious illness that reduces
immunity (such as long-term chronic illness or HIV infection). These should be considered
only if there are other symptoms; yeast infection alone is common and usually easily
prevented or treated.
Treatment of lower reproductive tract infections includes the administration of antibi-
otics, such as nitroimidazoles, lincosamides, macrolides (e.g., erythromycin) and, in some
circumstances, penicillins [8], or antifungal drugs, such as fluconazole or amphotericin
B [29]. Pharmacotherapy of infections depends on the drug susceptibility of microor-
ganisms, and on the bioavailability of drugs. Distribution to the body’s tissues after a
drug enters the systemic circulation, is generally uneven because of differences in blood
perfusion, tissue binding (e.g., because of lipid content), regional pH, and permeability
of cell membranes. Unfortunately, the bioavailability of antibiotics or antifungal drugs
in vaginal tissues cannot always be predicted and can be much lower, hence the main
regiment of the metronidazole or clindamycin, clotrimazole, miconazole, and tioconazole
preparations is intravaginal [29–31], and the recommended route of admission of other
antibiotics is oral. According to Sobel et al., the susceptibility testing for women with
vulvovaginal candidiasis appears to be unjustified [29], whereas antibiotics should be
taken after drug-susceptibility testing. Data from clinical trials indicate that a woman’s
response to the therapy of bacterial vaginosis, and the likelihood of relapse or recurrence,
are not affected by treatment of her sex partner(s), but routine treatment of sex partners is
recommended in vulvovaginal candidiasis [8].
The presented research results also show another additional aspect of everyday prac-
tice in gynaecological proceedings: diagnostics of lower genital tract infections. Vaginal
infections should be diagnosed using both clinical criteria—Amsel test—as a screening
test for BV diagnostics and microbiological Nugent criteria as a confirmation test with
inoculation in doubtful situations or lack of effect after initial treatment [32]. Unfortunately,
in the analyzed cases only the Amsel criteria and culture methods were used, omitting the
preparations that were not ordered by the physicians-in-charge, and the experience of the
authors indicate that this may be a problem not only in Silesian province, but in diagnostics
of lower urinary tract infections in Poland. This is the more significant problem, that a
large variety of etiological factors of genital tract infections (in our studies, from 18.8% of
patients, we isolated rare species of microorganisms) indicates the necessity of using better
and better methods of identification, not only morphotypes in microscopic examination
(e.g., Peptostreptococcus spp., Atopobium vaginae described in the literature), but also studies
of non-microbial microorganisms (e.g., Atopobium vaginae) [33].
This retrospective laboratory-based study had some limitations. Demographic in-
formation for the study population was limited, thus, data on the use of contraceptives,
sexual activity and partners, sign and symptoms, such as vulvar pruritus, were unavail-
able, as well as signs of atypical infections like cervicitis. Despite the large population
constituting the study group, the limitation of the study is also the fact that it only covers
one Silesia province. The most important limitation of the study was not using samples for
Nugent scoring.
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D.; Szczapa, J.; Klamka, J.; et al. Early-onset Infections of Very-low-birth-weight Infants in Polish Neonatal Intensive Care Units.
Pediatr. Infect. Dis. J. 2012, 31, 691–695. [CrossRef] [PubMed]
25. Tomusiak, A.; Heczko, P.B.; Janeczko, J.; Adamski, P.; Pilarczyk-Zurek, M.; Strus, M. Bacterial infections of the lower genital tract
in fertile and infertile women from the southeastern Poland. Ginekol. Pol. 2013, 84, 352–358. [CrossRef] [PubMed]
26. Subtil, D.; Brabant, G.; Tilloy, E.; Devos, P.; Canis, F.; Fruchart, A.; Bissinger, M.-C.; Dugimont, J.-C.; Nolf, C.; Hacot, C.; et al. Early
clindamycin for bacterial vaginosis in pregnancy (PREMEVA): A multicentre, double-blind, randomised controlled trial. Lancet
2018, 392, 2171–2179. [CrossRef]
27. Ekiel, A.; Friedrk, D.; Romanik, M.; Martirosian, G. The Incidence of Candida spp. in the Vagina of Women with Dysplastic Changes in
the Cervical Epithelium Mikologia Lekarska; Wyd. Medyczne Cornetis: Wrocław, Poland, 2006; p. 13. (In Polish)
28. Babu, G.; Singaravelu, B.G.; Srikumar, R.; Reddy, S.V.; Kokan, A. Comparative Study on the Vaginal Flora and Incidence of
Asymptomatic Vaginosis among Healthy Women and in Women with Infertility Problems of Reproductive Age. J. Clin. Diagn.
Res. 2017, 11, DC18–DC22. [CrossRef]
29. Sobel, J.D.; Zervos, M.; Reed, B.D.; Hooton, T.; Soper, D.; Nyirjesy, P.; Heine, M.W.; Willems, J.; Panzer, H. Fluconazole
Susceptibility of Vaginal Isolates Obtained from Women with Complicated Candida Vaginitis: Clinical Implications. Antimicrob.
Agents Chemother. 2003, 47, 34–38. [CrossRef]
30. Sobel, J.D. Antimicrobial Resistance in Vulvovaginitis. Curr. Infect. Dis. Rep. 2001, 3, 546–549. [CrossRef]
31. Bhattacharya, S.; Sae-Tia, S.; Fries, B.C. Candidiasis and Mechanisms of Antifungal Resistance. Antibiotics 2020, 9, 312. [CrossRef]
32. Rodrigues, F.S.; Peixoto, S.; Adami, F.; Alves, B.D.C.A.; Gehrke, F.D.S.; Azzalis, L.A.; Junqueira, V.B.D.C.; Fonseca, F.L.A. Proposal
of a new cutoff for Nugent criteria in the diagnosis of bacterial vaginosis. J. Microbiol. Methods 2015, 115, 144–146. [CrossRef]
33. Gaydos, C.A.; Beqaj, S.; Schwebke, J.R.; Lebed, J.; Smith, B.; Davis, T.E.; Fife, K.H.; Nyirjesy, P.; Spurrell, T.; Furgerson, D.; et al.
Clinical Validation of a Test for the Diagnosis of Vaginitis. Obstet. Gynecol. 2017, 130, 181–189. [CrossRef]
